Eyepoint Pharmaceuticals (NASDAQ:EYPT) Rating Lowered to Underweight at JPMorgan Chase & Co.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) was downgraded by JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a research note issued on Tuesday, Briefing.com reports.

A number of other brokerages have also issued reports on EYPT. Stifel Nicolaus assumed coverage on shares of Eyepoint Pharmaceuticals in a research report on Thursday, July 16th. They issued a “buy” rating and a $40.00 target price for the company. Royal Bank Of Canada restated a “sector perform” rating and set a $5.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, August 18th. Guggenheim lowered shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday. Mizuho reiterated a “neutral” rating and issued a $0.50 price objective on shares of Eyepoint Pharmaceuticals in a report on Tuesday. Finally, Wall Street Zen upgraded shares of Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, September 27th. Two investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Eyepoint Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $22.25.

Eyepoint Pharmaceuticals Stock Performance

NASDAQ:EYPT opened at $0.44 on Tuesday. The stock has a market cap of $37.93 million, a price-to-earnings ratio of -0.12 and a beta of 1.67. Eyepoint Pharmaceuticals has a 1 year low of $0.40 and a 1 year high of $19.11. The business has a fifty day moving average of $4.77 and a 200-day moving average of $10.30.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The company had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. On average, equities research analysts predict that Eyepoint Pharmaceuticals will post -3.51 EPS for the current year.

Institutional Trading of Eyepoint Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC boosted its stake in Eyepoint Pharmaceuticals by 22.6% during the first quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock valued at $46,419,000 after buying an additional 663,439 shares in the last quarter. Commodore Capital LP acquired a new position in Eyepoint Pharmaceuticals during the first quarter worth about $36,414,000. Hsbc Holdings PLC bought a new stake in Eyepoint Pharmaceuticals in the first quarter worth about $10,743,000. Stempoint Capital LP raised its position in Eyepoint Pharmaceuticals by 129.1% in the first quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock worth $10,451,000 after acquiring an additional 456,915 shares in the last quarter. Finally, Principia Wealth Advisory LLC raised its position in Eyepoint Pharmaceuticals by 2.6% in the second quarter. Principia Wealth Advisory LLC now owns 649,944 shares of the company’s stock worth $9,294,000 after acquiring an additional 16,180 shares in the last quarter. Institutional investors own 99.41% of the company’s stock.

Key Eyepoint Pharmaceuticals News

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: EyePoint plans to reduce operating expenses and concentrate resources on its late-stage DURAVYU program for DME. The narrower focus could extend the company’s cash runway and preserve value in its remaining lead program. EyePoint Announces Strategic Prioritization
• Neutral Sentiment: Unusual options activity included purchases of 7,885 call contracts, approximately 69% above typical daily call volume. This may indicate speculative interest or expectations of a rebound, but it does not change the company’s fundamental outlook.
• Negative Sentiment: EyePoint reported disappointing topline results from the LUCIA Phase 3 trial of DURAVYU in wet AMD. The setback led the company to halt related clinical trials early, removing a major potential catalyst and raising doubts about the drug’s commercial prospects in the market. EyePoint Announces Topline Results from LUCIA
• Negative Sentiment: The company announced a 53% workforce reduction as part of its restructuring after the clinical-trial setback. Although the cuts should lower expenses, they also signal a substantially reduced operating plan and weaker near-term growth prospects. EyePoint Pharmaceuticals to Cut 53% of Workforce
• Negative Sentiment: Guggenheim downgraded EYPT from “buy” to “neutral,” while Jefferies moved from “buy” to “hold.” Jefferies assigned a $1.00 price target, implying substantial upside from the current level, but the downgrade reflects sharply reduced confidence following the LUCIA results.
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities-law violations on behalf of shareholders who suffered losses. The inquiry adds legal and reputational risk, although it does not establish wrongdoing. EyePoint Pharmaceuticals Investigation Notice

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.